Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) Return on Equity (2020 - 2026)

Barinthus Biotherapeutics (BRNS) has disclosed Return on Equity for 7 consecutive years, with 0.74% as the latest value for Q1 2026.

  • For Q1 2026, Return on Equity fell 21.0% year-over-year to 0.74%; the TTM value through Mar 2026 reached 0.74%, down 21.0%, while the annual FY2025 figure was 0.65%, 26.0% down from the prior year.
  • Return on Equity hit 0.74% in Q1 2026 for Barinthus Biotherapeutics, up from 0.84% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.04% in Q3 2022 and bottomed at 0.84% in Q4 2025.
  • Average Return on Equity over 5 years is 0.37%, with a median of 0.38% recorded in 2023.
  • On a YoY basis, Return on Equity climbed as much as 39bps in 2022 and fell as far as -76bps in 2022.
  • Barinthus Biotherapeutics' Return on Equity stood at 0.02% in 2022, then crashed by -1858bps to 0.38% in 2023, then fell by -10bps to 0.42% in 2024, then tumbled by -98bps to 0.84% in 2025, then grew by 11bps to 0.74% in 2026.
  • According to Business Quant data, Return on Equity over the past three periods came in at 0.74%, 0.84%, and 0.81% for Q1 2026, Q4 2025, and Q3 2025 respectively.